DUMAC Inc
SGMT icon

DUMAC Inc’s Sagimet Biosciences SGMT Stock Holding History

DUMAC Inc’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-71,192
Closed -$550K – 26
2026
Q2 		$550K Hold
71,192
– – 0.05% 14
2026
Q1 		$372K Hold
71,192
– – 0.05% 9
2025
Q4 		$421K Buy
+71,192
New +$512K 0.06% 9
2025
Q2 		$572K Sell
75,000
-72,351
-49% -$305K 3.59% 6
2025
Q1 		$480K Sell
147,351
-16,163
-10% -$67.8K 1.92% 9
2024
Q4 		$736K Sell
163,514
-25,880
-14% -$131K 1.14% 7
2024
Q3 		$525K Hold
189,394
– – 1.7% 8
2024
Q2 		$648K Hold
189,394
– – 2.07% 8
2024
Q1 		$1.03M Sell
189,394
-14,729
-7% -$106K 3.72% 7
2023
Q4 		$1.11M Hold
204,123
– – 3.41% 7
2023
Q3 		$1.8M Buy
+204,123
New +$2.72M 4.82% 6

Other funds holding SGMT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

DUMAC Inc's SGMT Position: Q3 2026 in Review

DUMAC Inc sold out of Sagimet Biosciences (SGMT) in Q3 2026, closing a stake of 71,192 shares — an estimated $550K sold.

DUMAC Inc first reported a position in SGMT in Q3 2023 and held it in 11 quarters. The position peaked at $1.8M in Q3 2023. 48 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

  • DUMAC Inc reported no remaining Sagimet Biosciences position as of Q3 2026 after selling out during the quarter.
  • DUMAC Inc sold 71,192 Sagimet Biosciences shares in Q3 2026, an estimated $550K.
  • DUMAC Inc first reported a position in Sagimet Biosciences in Q3 2023 and held it in 11 quarters.
  • DUMAC Inc's Sagimet Biosciences position peaked at $1.8M in Q3 2023.
  • 48 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on DUMAC Inc's 13F filing for Q3 2026, filed 10 Nov 2026.